ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

2025 Annual Review of the 2024 Pharmaceutical Drug Development Market Featuring Pfizer, Merck, Novartis, Johnson & Johnson, Abbvie, F.Hoffman-La Roche, Astrazeneca, GSK, Bristol Myers-Squibb, Sanofi - ResearchAndMarkets.com

The "Pharmaceutical Drug Development Annual Review - 2024" report has been added to ResearchAndMarkets.com's offering.

This report investigates the year 2024 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.

This report gives important, expert insight you won't find in any other source. 21 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines.

This report is required reading for:

  • Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
  • Companies that are interested in entering the biopharmaceutical space and where best to focus on
  • Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
  • Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities

Reasons to Buy

  • Insights on how drug development in 2024 may impact future approvals
  • Insights on how drug approvals in 2024 may impact future drug development and approval trends
  • Sales and regulatory-based insights into 2024 covering various drugs and companies

Key Topics Covered:

1 Executive Summary

2 2024 Pipeline Development

2.1 Top pipeline therapy areas

2. 2 Pipeline drugs by highest development stage

2.3 Top drugs by molecule type

2.4 Top drugs by target

3 2024 Approvals

3.1 FDA, EMA, Japan regulatory approvals, 2022-2024

3.2 US Fast Track Designation approvals, 2022-2024

3.3 Rare Pediatric disease designation approvals, 2022-2024

4 2024 Sales

4.1 2023 vs 2024 sales

4.2 2023 vs 2024 company market capitalization

5 Key Findings

6 Appendix

Companies Featured

  • Pfizer
  • Merck & Co
  • Novartis AG
  • Johnson & Johnson
  • Abbvie
  • F.Hoffman-La Roche Ltd
  • Bristol-Myers Squibb Co
  • Astrazeneca Plc
  • GSK plc
  • Bristol Myers-Squibb Co
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/hctc4z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.